Clinical experience with ASD-based adjuvant therapy for wound regeneration in cats

Wound healing in cats remains a clinically relevant challenge due to species-specific anatomical features, prolonged inflammatory responses, and a relatively high risk of delayed epithelialization. The present case report evaluated the clinical efficacy and systemic safety of topical application of ASD fraction 3 ointment as an adjuvant therapy for the treatment of a cervical skin wound in a cat, with particular emphasis on wound healing dynamics, inflammatory status, metabolic balance, and potential adverse effects. At the initiation of treatment (Day 1), the cat presented with an open, round wound located in the cervical region, measuring 4.75 cm in diameter. The wound surface exhibited moderate edema, hyperemia of the surrounding tissues, and serosanguineous exudation, consistent with the inflammatory phase of wound healing. Topical ASD fraction 3 ointment was applied according to the treatment protocol, and the animal was monitored through regular clinical examinations as well as serial hematological and biochemical assessments conducted on Days 1, 7, 14, and 21. By Day 7 of treatment, a marked reduction in wound size was observed, with the wound area decreasing to approximately 65–70 % of the initial value. This reduction was accompanied by a noticeable decrease in exudation, contraction of the wound margins, and formation of viable granulation tissue. By day 14, further wound contraction was recorded, with the residual wound area reduced to approximately 20–25 % of baseline, indicating active epithelialization and progression toward tissue repair. Complete clinical wound healing was achieved by Day 21, characterized by full restoration of skin integrity and the formation of a thin, elastic scar without signs of inflammation or local complications. Hematological evaluation at baseline revealed moderate leukocytosis with neutrophilia, reflecting an active localized inflammatory response. During the course of treatment, leukocyte counts and differential parameters progressively normalized, indicating effective resolution of inflammation. Biochemical analysis demonstrated transient hypoproteinemia and hypoalbuminemia at the initial stage, followed by gradual normalization during healing. Liver and renal function markers remained within physiological reference ranges throughout the observation period, suggesting the absence of systemic toxicity associated with the topical use of ASD fraction 3 ointment. In conclusion, topical application of ASD fraction 3 ointment was associated with favorable wound healing dynamics, controlled inflammatory response, maintenance of metabolic balance, and no detectable adverse systemic effects. These findings suggest that ASD-based topical therapy may represent a promising adjunctive option for wound management in cats, warranting further controlled and comparative studies.